Boehringer Ingelheim Advances DLL3-Targeting T-Cell Engager Obrixtamig Directly to Phase 3 First-Line Small Cell Lung Cancer Trial
核心洞察
Boehringer Ingelheim is advancing its DLL3 (搜索)-targeting T-cell engager obrixtamig directly from phase 1 to a pivotal phase 3 trial in first-line extensive-stage small cell lung cancer.
The Dareon-Lung-1 trial will evaluate obrixtamig combined with standard-of-care Tecentriq plus chemotherapy versus Tecentriq plus chemotherapy alone, with overall survival as the primary endpoint.
Phase 1 data from Dareon-8 showed a 68% response rate among 28 patients, with 52% remaining progression-free at nine months, suggesting potential durability advantages.
Boehringer Ingelheim is taking an aggressive approach with its DLL3 (搜索)-targeting T-cell engager obrixtamig, advancing the therapy directly from phase 1 into a pivotal phase 3 trial in first-line extensive-stage small cell lung cancer (ES-SCLC). The strategic move, revealed through a recent clinicaltrials.gov posting, positions the company to compete in earlier treatment settings rather than the crowded second-line space where Amgen's competing DLL3-targeting bispecific Imdelltra already holds full approval.
Phase 3 Trial Design Targets First-Line Setting
The new phase 3 trial, designated Dareon-Lung-1, will evaluate obrixtamig in combination with the standard-of-care regimen of Tecentriq plus chemotherapy versus Tecentriq plus chemotherapy alone. Overall survival serves as the primary endpoint for this pivotal study.
This approach mirrors Amgen's strategy with its front-line pivotal trial in ES-SCLC, Dellphi-312, which tests Imdelltra plus Imfinzi and chemotherapy as induction therapy, followed by Imdelltra plus Imfinzi as maintenance treatment.
Promising Phase 1 Data Shows Durability Potential
Boehringer's pivotal trial design builds on encouraging data presented at ESMO from the uncontrolled phase 1 Dareon-8 study. This trial tested induction therapy with obrixtamig plus Tecentriq and chemotherapy, followed by maintenance with obrixtamig plus Tecentriq, in first-line ES-SCLC patients.
Among 28 patients enrolled in the study, the response rate reached 68%, which is comparable to historical chemo-immunotherapy outcomes in this treatment setting. However, durability may represent obrixtamig's key differentiating factor. ESMO discussant Dr. Helena Linardou highlighted the potential benefit in progression-free survival, noting that 52% of patients remained progression-free at nine months.
Safety Profile Supports Earlier-Line Strategy
The safety profile observed in Dareon-8 supports Boehringer's strategy of moving the T-cell engager into earlier treatment lines. Moving T-cell engagers into earlier settings, when patients are generally fitter, could help mitigate cytokine release syndrome, a class-defining toxicity associated with these therapies.
In the Dareon-8 study, 50% of patients experienced cytokine release syndrome, but importantly, all cases were grade 1 or 2 events, suggesting a manageable safety profile in the first-line setting.
Strategic Questions Around Combination Approach
The inclusion of checkpoint inhibitors in both companies' regimens raises strategic questions about optimal combination strategies. As noted by the ESMO discussant, immunotherapy has historically demonstrated only modest activity in first-line SCLC. Despite this observation, both Boehringer and Amgen have chosen to retain checkpoint inhibitors in their respective treatment regimens, and neither company appears ready to test their T-cell engagers in combination with chemotherapy alone in this setting.
Competitive Landscape in DLL3-Targeting Therapies
The competitive dynamics in DLL3 (搜索)-targeting therapies continue to evolve, with Amgen maintaining multiple phase 3 studies in first-line ES-SCLC maintenance and in limited-stage SCLC, a potentially curative treatment setting. The question remains whether Boehringer will follow suit with similar expansion into these additional indications as the companies compete for market position in this challenging cancer type.